MCK - McKesson Introduces FDA-Approved Prostate Cancer Drug | Benzinga
McKesson Corporation's (NYSE: MCK) Biologics by McKesson, its independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Accord BioPharma, Inc. as an exclusive specialty pharmacy provider for CAMCEVI (leuprolide) 42mg injection emulsion for subcutaneous use. CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer.
CAMCEVI was approved by the FDA on May 25, 2021.
The availability of the FDA-approved drug is expected to significantly solidify McKesson's foothold in the global prostate cancer treatment space.
Significance of the Availability
Per McKesson, CAMCEVI is an important advancement in oncology, which is expected to improve patients' long-term outcomes. McKesson's management believes that the availability of the convenient therapy will likely provide an option to treat patients with advanced prostate cancer.
Industry Prospects
Per a report by Grand View Research, the global prostate cancer therapeutics market size was estimated at $12.12 billion in 2022 ...